Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Cybin Inc

Healthcare US CYBN

NoneUSD
0.00(0%)

Last update at 2026-04-09T21:02:35.388327Z

Day Range

--
LowHigh

52 Week Range

0.210.74
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap166.42M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-52.16500M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.31100M
  • Diluted EPS TTM-0.19

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Type yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Income before tax -47.49000M -67.63100M -32.22000M -
Minority interest - - - -
Net income -40.03700M -71.42400M -32.22000M -
Selling general administrative 24.49M 44.79M 22.48M -
Selling and marketing expenses 0.88M 1.47M 4.95M -
Gross profit - 0.00000M 0.20M -
Reconciled depreciation 0.25M 0.17M 0.05M -
Ebit -54.94300M -63.59700M -30.46400M -1.95360M
Ebitda -54.69200M -63.42900M -30.41500M -
Depreciation and amortization 0.25M 0.17M 0.05M -
Non operating income net other - - - -
Operating income -54.94300M -63.59700M -30.46400M -
Other operating expenses 51.52M 63.84M 31.39M -
Interest expense 7.45M 0.24M 0.01000M 0.00000M
Tax provision - - - -
Interest income 0.60M 0.24M 0.06M -
Net interest income 0.60M 0.24M 0.05M -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -7.45300M 3.79M 0.01000M -
Total revenue 0.00000M 0.00000M 0.86M -
Total operating expenses 51.52M 63.84M 30.72M -
Cost of revenue - 0.00000M 0.66M -
Total other income expense net 7.45M -4.03400M -1.74600M -
Discontinued operations - - - -
Net income from continuing ops -47.49000M -67.63100M -32.22000M -
Net income applicable to common shares -47.49000M -67.63100M -32.22000M -1.94400M
Preferred stock and other adjustments - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Type yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Total assets 53.90M 84.06M 92.11M 1.71M
Intangible assets 5.47M 2.08M 1.70M 1.70M
Earning assets - - - -
Other current assets 1.77M 1.34M 1.34M 0.02M
Total liab 5.66M 7.91M 5.99M 0.26M
Total stockholder equity 48.23M 76.16M 86.12M 1.45M
Deferred long term liab - - - -
Other current liab - 2.65M -0.36200M 0.26M
Common stock 158.16M 141.45M 100.68M 2.19M
Capital stock 158.16M 141.45M 100.68M 2.19M
Retained earnings -148.15100M -100.66100M -33.03000M -0.81000M
Other liab - - 1.09M -
Good will 24.79M 22.89M 23.37M 23.37M
Other assets - - - -
Cash 16.63M 53.64M 64.03M 1.54M
Cash and equivalents - - - -
Total current liabilities 5.66M 7.91M 4.90M 0.26M
Current deferred revenue - - - -
Net debt -16.63300M -53.64100M -64.02600M -1.54500M
Short term debt - - - -
Short long term debt - - - -
Short long term debt total - - - -
Other stockholder equity 40.26M 35.73M 18.45M 0.07M
Property plant equipment 0.45M 0.49M 0.56M -
Total current assets 23.18M 58.35M 66.48M 1.64M
Long term investments 0.00000M 0.24M 0.00000M 0.07M
Net tangible assets 17.97M 51.18M 61.05M 1.45M
Short term investments - - - -
Net receivables 3.05M 2.10M 1.33M 0.07M
Long term debt - - - -
Inventory 1.73M 1.27M -0.21200M -
Accounts payable 5.66M 5.26M 5.26M 0.26M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income -2.03500M -0.36600M 0.02M 0.02M
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other - - -0.24200M -25.62800M
Deferred long term asset charges - - - -
Non current assets total 30.71M 25.71M 25.63M 0.07M
Capital lease obligations - - - -
Long term debt total - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Type yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31
Investments -3.30900M -0.77000M -1.18900M -0.17040M
Change to liabilities 0.40M 2.47M 1.79M 0.63M
Total cashflows from investing activities -3.30900M -0.77000M -1.18900M -0.17040M
Net borrowings - - - -
Total cash from financing activities 13.56M 35.78M 82.72M 5.26M
Change to operating activities -0.89000M -1.48300M -1.06600M -0.04800M
Net income -47.49000M -67.63100M -32.22000M -1.94400M
Change in cash -37.00800M -10.38500M 62.48M 3.71M
Begin period cash flow 53.64M 64.03M 1.54M -
End period cash flow 16.63M 53.64M 64.03M 1.54M
Total cash from operating activities -47.43100M -45.20700M -19.02700M -1.38480M
Issuance of capital stock 13.20M 31.51M 76.24M -
Depreciation 0.25M 0.17M 0.05M 0.05M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - 0.00000M -0.51100M -0.51100M
Change to account receivables -0.94800M -0.77300M -1.48500M -0.17760M
Sale purchase of stock - - - -
Other cashflows from financing activities 0.36M 4.27M 6.49M -0.14928M
Change to netincome 1.25M 22.04M 14.41M 0.15M
Capital expenditures 3.31M 0.52M 0.23M 0.14M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital -1.43700M 0.21M -1.26700M -
Stock based compensation 4.69M 18.03M 11.55M -
Other non cash items 0.32M 4.01M 1.96M -
Free cash flow -50.74000M -45.72700M -19.25800M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CYBN
Cybin Inc		 - -% - - - 278.25 4.50 313.59 -2.7792
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

Cybin Inc

100 King Street West, Toronto, ON, Canada, M5X 1C9

Key Executives

Name Title Year Born
Mr. Eric So L.L.B., LLB Co-Founder, Pres & Exec. Chairman 1976
Mr. Douglas L. Drysdale Chief Exec. Officer 1970
Mr. Paul Glavine Co-Founder, Chief Growth Officer & Director 1989
Mr. John Kanakis Co-Founder 1980
Mr. Greg Cavers Chief Financial Officer 1971
Mr. Aaron Bartlone Chief Operating Officer NA
Dr. Alex L. Nivorozhkin Ph.D. Chief Scientific Officer 1960
Ms. Leah Gibson VP of Investor Relations & Strategic Communications NA
Ms. Lori Challenger Chief Compliance, Ethics & Admin. Officer NA
Mr. Gabriel Fahel Chief Legal Officer & Corp. Sec. 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions